It is the position of PSNA that medical marijuana is worthy of further rigorous clinical testing. To truly weigh the risks and benefits of medical marijuana, there must be federal-level open discussions regarding the conversion of marijuana from a Schedule I to Schedule II drug classification. Schedule II classification would allow testing of consistent grade medical marijuana in a randomized controlled fashion to ascertain the drug’s risk/benefit profile for a multitude of illnesses and symptoms.

“PSNA would like to thank Senator Folmer for bringing nurses to the table to discuss this important patient-driven initiative,” stated PSNA CEO Betsy M. Snook, MEd, BSN, RN.

About The Western PA Healthcare News Team

Throughout the year, our writers feature fresh, in-depth, and relevant information for our audience of 40,000+ healthcare leaders and professionals. As a healthcare business publication, we cover and cherish our relationship with the entire health care industry including administrators, nurses, physicians, physical therapists, pharmacists, and more. We cover a broad spectrum from hospitals to medical offices to outpatient services to eye surgery centers to university settings. We focus on rehabilitation, nursing homes, home care, hospice as well as men’s health, women’s heath, and pediatrics.